First Trust Advisors LP decreased its holdings in Amedisys Inc (NASDAQ:AMED) by 11.0% in the first quarter, HoldingsChannel reports. The institutional investor owned 40,056 shares of the health services provider’s stock after selling 4,932 shares during the period. First Trust Advisors LP’s holdings in Amedisys were worth $4,937,000 at the end of the most recent reporting period.
Several other hedge funds have also made changes to their positions in the company. Connor Clark & Lunn Investment Management Ltd. grew its holdings in Amedisys by 197.8% during the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 23,225 shares of the health services provider’s stock worth $2,863,000 after acquiring an additional 15,425 shares during the last quarter. Alpha Quant Advisors LLC lifted its position in Amedisys by 137.0% during the 1st quarter. Alpha Quant Advisors LLC now owns 237 shares of the health services provider’s stock valued at $29,000 after purchasing an additional 137 shares during the period. National Asset Management Inc. acquired a new position in Amedisys during the 1st quarter valued at about $211,000. 361 Capital LLC lifted its position in Amedisys by 9.4% during the 1st quarter. 361 Capital LLC now owns 22,767 shares of the health services provider’s stock valued at $2,806,000 after purchasing an additional 1,957 shares during the period. Finally, ETF Managers Group LLC acquired a new position in Amedisys during the 1st quarter valued at about $511,000. Institutional investors own 86.30% of the company’s stock.
Shares of NASDAQ:AMED opened at $117.60 on Wednesday. The company has a market capitalization of $3.71 billion, a P/E ratio of 32.40, a PEG ratio of 1.44 and a beta of 1.40. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.91 and a current ratio of 0.91. Amedisys Inc has a fifty-two week low of $80.01 and a fifty-two week high of $140.91.
A number of research firms have issued reports on AMED. BidaskClub upgraded shares of Amedisys from a “sell” rating to a “hold” rating in a research report on Wednesday, June 5th. ValuEngine downgraded shares of Amedisys from a “buy” rating to a “hold” rating in a research report on Tuesday, May 14th. Raymond James upgraded shares of Amedisys from a “market perform” rating to an “outperform” rating and set a $140.00 target price on the stock in a research report on Thursday, May 2nd. Barclays upped their target price on shares of Amedisys from $115.00 to $120.00 and gave the company an “equal weight” rating in a research report on Thursday, March 21st. Finally, Craig Hallum cut their target price on shares of Amedisys from $132.00 to $124.00 and set a “hold” rating on the stock in a research report on Friday, March 1st. They noted that the move was a valuation call. Nine research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $129.89.
In related news, Director Bruce D. Perkins bought 2,500 shares of the company’s stock in a transaction on Wednesday, May 15th. The shares were purchased at an average cost of $111.84 per share, for a total transaction of $279,600.00. Following the acquisition, the director now owns 22,088 shares of the company’s stock, valued at approximately $2,470,321.92. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, insider Michael Paul North sold 5,248 shares of the firm’s stock in a transaction that occurred on Wednesday, June 5th. The stock was sold at an average price of $115.01, for a total transaction of $603,572.48. The disclosure for this sale can be found here. Insiders sold a total of 30,168 shares of company stock worth $3,456,343 over the last quarter. 2.90% of the stock is currently owned by corporate insiders.
WARNING: This article was published by WKRB News and is the property of of WKRB News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://www.wkrb13.com/2019/06/12/first-trust-advisors-lp-sells-4932-shares-of-amedisys-inc-nasdaqamed.html.
Amedisys Company Profile
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.
Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc (NASDAQ:AMED).
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.